Pipeline
CTIM-76: Claudin 6 x CD3
CTIM-76 is a bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding scFv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile. Research has demonstrated that CTIM-76 is potent with specific lysis of CLDN6+ cancer cells over normal cells and can activate cytotoxic T cells without concomitant activation of free cytokines – critical determinants of immunotherapy safety and activity.
CT-202: Nectin-4 x CD3
CT-202 is a bispecific antibody engineered in an IgG format, featuring two Nectin-4 binding arms and two CD3-binding single-chain Fv domains, along with a silenced Fc region designed to be functionally monovalent. This structure helps prevent unwanted T-cell activation and improves safety. While Nectin-4 is present in healthy skin, sweat glands, and hair follicles, making targeted therapies prone to dermatological side effects, CT-202 employs pH-dependent binding to both Nectin-4 and CD3, minimizing interaction with healthy tissues and optimizing selectivity for tumor cells within the tumor microenvironment.